Buy Retatrutide — Triple Agonist for Weight Loss
Retatrutide is a first-in-class synthetic triple agonist of the GLP-1, GIP, and glucagon receptors, developed by Eli Lilly as the next evolution of the incretin class following tirzepatide. Phase 2 trial results published in 2023 demonstrated unprecedented weight loss magnitudes, placing retatrutide at the forefront of pharmacological research for obesity and metabolic disease.Mechanism of actionRetatrutide simultaneously activates three distinct receptors that govern energy balance. GLP-1 and GIP contribute insulin secretion and appetite regulation, while glucagon receptor activation increases basal energy expenditure and enhances hepatic lipid oxidation. The triple-agonist architecture is hypothesised to drive weight loss beyond what dual agonism alone can achieve.Evidence from peer-reviewed researchA landmark 2023 Phase 2 paper in the New England Journal of Medicine reported mean weight reductions of up to 24.2% at 48 weeks in participants receiving the highest retatrutide dose — a result substantially greater than tirzepatide's SURMOUNT-1 data at the same time point. A companion 2023 Lancet paper demonstrated glycaemic efficacy in type 2 diabetes with similarly favourable weight effects.Typical research protocolsRetatrutide is administered subcutaneously once weekly in published protocols, with stepwise dose escalation over 4–12 weeks to improve tolerability. As with other incretins, gastrointestinal side-effects are most common during dose escalation and subside over time.Quality and purityPEPTEX retatrutide is supplied lyophilised to ≥99% purity, verified by HPLC and mass spectrometry. Certificates of analysis available on request.Storage and handlingStore lyophilised retatrutide at −20 °C, protected from light, for up to 24 months. After reconstitution with bacteriostatic water, store at 2–8 °C and use within 12 weeks.
Price: EUR | Brand: PEPTEX | In Stock | EU-wide delivery, 3-5 business days
Rating: 5/5 (433 reviews)
Customer Reviews
Elena S. — ★★★★★
Packaging is always immaculate. Cold chain maintained perfectly on all four orders. The retat itself works as the published research suggests. Consistent quality.
simone_it — ★★★★★
The triple agonist mechanism is noticeable compared to tirzepatide. I ran both (tirz for 4 months, then switched to retat). The energy expenditure component is real — I'm warmer, more energetic, and the fat loss pace picked up even though I'm already lean
Filippo — ★★★★★
Initially skeptical about the Phase II hype. Ordered a small amount to test. Results were convincing enough that I've now ordered three times. Peptex support answered my dosing questions within hours.
Bram87 — ★★★★
Decent product. Took about three weeks longer than tirzepatide to really feel the appetite suppression, but once it kicked in the effect was stronger. The GI adjustment period was similar. Would rate 5 if the titration phase wasn't so slow.
Oskar88 — ★★★★★
Partner and I run retatrutide together. Both on our second cycle. He's more focused on the metabolic effects, I'm interested in the liver fat data. Both very happy with the quality and consistency from peptex.
Available Sizes
- 10mg — 129 EUR
- 30mg — 199 EUR
- 60mg — 349 EUR
Storage Recommendations
| Condition | Temperature | Duration |
|---|---|---|
| Lyophilised | -20°C | Up to 24 months |
| Reconstituted | 2-8°C | Up to 12 weeks with bacteriostatic water |
Research References
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — NEJM / PubMed (2023)
- Retatrutide in type 2 diabetes — Phase 2 — Lancet / PubMed (2023)
Frequently Asked Questions
What is Retatrutide and what is its advantage over other weight loss peptides?
Retatrutide is a next-generation triple-action peptide that simultaneously targets three receptor types: GLP-1, GIP, and glucagon. It is the only peptide with triple agonism, providing the most comprehensive approach to weight loss. GLP-1 and GIP reduce appetite and hunger, while glucagon receptor activation additionally increases the body's energy expenditure. In clinical studies, participants lost an average of 20–24% of their initial body weight — one of the highest results among all existing weight management peptides.
How to properly take Retatrutide and what dosage to choose?
Retatrutide is administered subcutaneously once per week. Dosage is gradually increased once per month following this schedule: 2 mg → 4 mg → 8 mg → 10 mg → 12 mg. After reaching the 12 mg weekly dose, the peptide is used until the target weight is achieved. The course can last several years. Retatrutide is most effective when combined with Cagrilintide — together they form one of the most powerful weight loss combinations. For storing the prepared solution up to 90 days, reconstitution in bacteriostatic water is recommended.
What results does Retatrutide provide and how much weight can I lose?
Retatrutide demonstrates some of the best results among all weight loss peptides. In clinical studies, average weight loss is 20–24% of initial body weight when following a proper diet. First results are noticeable within 2–4 weeks — appetite and snacking cravings decrease significantly. In the first 3 months, weight loss typically reaches 8–12%, and over 6–12 months at full dosage, results can reach 20–24%. Beyond weight loss, users report normalized metabolism, improved cholesterol levels, and increased energy.
How is Retatrutide different from Tirzepatide?
The main difference between Retatrutide and Tirzepatide is the number of target receptors. Tirzepatide acts on two receptors (GIP + GLP-1), while Retatrutide targets three (GLP-1 + GIP + glucagon). The additional activation of glucagon receptors in Retatrutide provides increased energy expenditure, making it more effective for significant excess weight. In studies, Retatrutide showed average weight loss of 20–24% compared to 15–22% for Tirzepatide. Retatrutide is the optimal choice for those who need the most significant weight reduction.
Is Retatrutide safe and what side effects are possible?
Retatrutide has a well-studied safety profile based on clinical research. The most common side effects are temporary mild nausea, stomach discomfort, and reduced appetite, which typically resolve within 1–2 weeks of adaptation. Gradual dose escalation (once per month) significantly minimizes these effects. Retatrutide does not contain stimulants, does not affect the nervous system, and does not cause dependence. It is administered just once per week, reducing the load on the body.
Where to buy Retatrutide in Europe with fast delivery?
You can order Retatrutide with delivery across Europe at peptex.shop. We offer original research-grade peptide, certified purity, secure temperature-controlled packaging, and fast delivery to all EU countries. Payment is available by bank card or cryptocurrency. Each order includes reconstitution and dosage instructions. Our support team will help select the optimal course.
💬 Комментарии